Abstract
Purpose. The influence of liver metastases on the pharmacokinetics of 5-fluorouracil (5-FU) and its metabolite 5,6-dihydrofluorouracil (DHFU) was studied in patients with liver metastases from gastrointestinal cancer (n=16) and compared with a control group of patients with nonmetastatic gastrointestinal cancer (n=18).
Methods. Patients were assigned to two different groups based on the presence of liver metastases. The percentage of hepatic replacement was determined with CT and ultrasonography and classified as <25%, 25–50% or >50% of the total liver volume. Chemotherapy consisted of leucovorin 20 mg/m2 per day plus 5-FU 425 mg/m2 per day, both for 5 days. Blood sampling was carried out on the first day of the first chemotherapy cycle. 5-FU and DHFU were quantified in plasma by HPLC. A four-compartment parent drug-metabolite model with nonlinear Michaelis-Menten elimination from the central compartment of the parent drug (5-FU) was applied to describe 5-FU and DHFU pharmacokinetics.
Results. No effect of liver metastases on 5-FU clearance was observed. The effects of 18 covariables on pharmacokinetic parameters were also studied in a univariate correlation analysis. Body surface area was positively correlated with the distribution volume of 5-FU in the central compartment and with Vmax (r=0.65 and r=0.54, respectively).
Conclusions. There is no need for dose adjustment of 5-FU as a standard procedure in patients with liver metastases and mild to moderate elevations in liver function tests.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Maring, J., Piersma, H., van Dalen, A. et al. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. Cancer Chemother Pharmacol 51, 167–173 (2003). https://doi.org/10.1007/s00280-002-0535-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00280-002-0535-2